| 1 |
33684260 | Structural Basis for Pore Blockade of the Human Cardiac Sodium Channel Nav 1.5 by the Antiarrhythmic Drug Quinidine*. | 2021 May 10 |
1 |
| 2 |
33712541 | Structure of human Nav1.5 reveals the fast inactivation-related segments as a mutational hotspot for the long QT syndrome. | 2021 Mar 16 |
1 |
| 3 |
34048814 | SCN5A compound heterozygosity mutation in Brugada syndrome: Functional consequences and the implication for pharmacological treatment. | 2021 Aug 1 |
1 |
| 4 |
34373326 | Functional cross-talk between phosphorylation and disease-causing mutations in the cardiac sodium channel Nav1.5. | 2021 Aug 17 |
1 |
| 5 |
33084224 | A combination of quinidine/mexiletine reduces arrhythmia in dilated cardiomyopathy in two patients with R814W SCN5A mutation. | 2020 Oct 20 |
1 |
| 6 |
29871609 | Rapid and effective response of the R222Q SCN5A to quinidine treatment in a patient with Purkinje-related ventricular arrhythmia and familial dilated cardiomyopathy: a case report. | 2018 Jun 5 |
2 |
| 7 |
17604185 | Action potential experiments complete hERG assay and QT-interval measurements in cardiac preclinical studies. | 2007 Sep-Oct |
1 |